Wedbush Reiterates Outperform on Bicara Therapeutics, Maintains $30 Price Target
Benzinga Newsdesk 7 months ago
NewsPrice TargetReiterationAnalyst Ratings
Wedbush analyst David Nierengarten reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and maintains $30 price target.
Wedbush analyst David Nierengarten reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and maintains $30 price target.